Tafadzwa L Chaunzwa1, Di Deng1, Eric C Leuthardt2, Stephen B Tatter3, Alireda M Mohammadi4, Gene H Barnett4, Veronica L Chiang1. 1. Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut. 2. Department of Neurosurgery, Washington University School of Medicine, St Louis, Missouri. 3. Department of Neurosurgery, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. 4. Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Radiosurgical failure following stereotactic radiosurgery for brain metastases can be attributed to tumor regrowth or radiation necrosis. MRI-guided laser thermal ablation (LTA) therapy has emerged as an option for treatment; however, previous literature demonstrates variable results across centers. OBJECTIVE: To assess the outcomes of LTA in the treatment of metastases failing radiosurgery across multiple centers and to determine if any treatment factors are predictive of outcome. METHODS: Clinical data for 30 patients across 4 centers were retrospectively reviewed. Patients were included if they received LTA therapy following radiosurgical failure due to radiation necrosis or tumor regrowth. Demographics, surgical data, and follow-up imaging and clinical information were collected. Linear regression analyses were performed to determine treatment factors that were associated with post-LTA outcome. RESULTS: The large majority of patients responded favorably to LTA treatment with low complication rates (23%), short length of stay (53% ≤ 2 d) and reductions in perilesional edema (63%). A total of 73.3% of patients stopped steroids and 48% saw improvement of their preoperative symptoms. Patients with better pre-LTA Karnofsky Performance Status had better survival. Patients who had lesions with more perilesional T2 change post-LTA had a better chance of weaning off steroids and obtaining symptomatic relief. CONCLUSION: MRI-guided laser thermal ablation therapy serves as a viable alternative to traditional treatment options for metastatic brain lesions failing radiosurgery. Although this study is limited by size and is retrospective, LTA therapy may result in symptomatic improvement and a more prominent reduction in fluid-attenuated inversion-recovery signal for larger lesions.
BACKGROUND: Radiosurgical failure following stereotactic radiosurgery for brain metastases can be attributed to tumor regrowth or radiation necrosis. MRI-guided laser thermal ablation (LTA) therapy has emerged as an option for treatment; however, previous literature demonstrates variable results across centers. OBJECTIVE: To assess the outcomes of LTA in the treatment of metastases failing radiosurgery across multiple centers and to determine if any treatment factors are predictive of outcome. METHODS: Clinical data for 30 patients across 4 centers were retrospectively reviewed. Patients were included if they received LTA therapy following radiosurgical failure due to radiation necrosis or tumor regrowth. Demographics, surgical data, and follow-up imaging and clinical information were collected. Linear regression analyses were performed to determine treatment factors that were associated with post-LTA outcome. RESULTS: The large majority of patients responded favorably to LTA treatment with low complication rates (23%), short length of stay (53% ≤ 2 d) and reductions in perilesional edema (63%). A total of 73.3% of patients stopped steroids and 48% saw improvement of their preoperative symptoms. Patients with better pre-LTA Karnofsky Performance Status had better survival. Patients who had lesions with more perilesional T2 change post-LTA had a better chance of weaning off steroids and obtaining symptomatic relief. CONCLUSION: MRI-guided laser thermal ablation therapy serves as a viable alternative to traditional treatment options for metastatic brain lesions failing radiosurgery. Although this study is limited by size and is retrospective, LTA therapy may result in symptomatic improvement and a more prominent reduction in fluid-attenuated inversion-recovery signal for larger lesions.
Authors: Nanthiya Sujijantarat; Christopher S Hong; Kent A Owusu; Aladine A Elsamadicy; Joseph P Antonios; Andrew B Koo; Joachim M Baehring; Veronica L Chiang Journal: J Neurooncol Date: 2020-06-29 Impact factor: 4.130
Authors: Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis Journal: Int J Hyperthermia Date: 2020-07 Impact factor: 3.914
Authors: Albert H Kim; Steven Tatter; Ganesh Rao; Sujit Prabhu; Clark Chen; Peter Fecci; Veronica Chiang; Kris Smith; Brian J Williams; Alireza M Mohammadi; Kevin Judy; Andrew Sloan; Zulma Tovar-Spinoza; James Baumgartner; Constantinos Hadjipanayis; Eric C Leuthardt Journal: Neurosurgery Date: 2020-09-01 Impact factor: 4.654
Authors: Balamurugan A Vellayappan; Tresa McGranahan; Jerome Graber; Lynne Taylor; Vyshak Venur; Richard Ellenbogen; Andrew E Sloan; Kristin J Redmond; Matthew Foote; Samuel T Chao; John H Suh; Eric L Chang; Arjun Sahgal; Simon S Lo Journal: Curr Treat Options Oncol Date: 2021-06-07
Authors: Elsa V Arocho-Quinones; Sean M Lew; Michael H Handler; Zulma Tovar-Spinoza; Matthew Smyth; Robert Bollo; David Donahue; M Scott Perry; Michael L Levy; David Gonda; Francesco T Mangano; Phillip B Storm; Angela V Price; Daniel E Couture; Chima Oluigbo; Ann-Christine Duhaime; Gene H Barnett; Carrie R Muh; Michael D Sather; Aria Fallah; Anthony C Wang; Sanjiv Bhatia; Kadam Patel; Sergey Tarima; Sarah Graber; Sean Huckins; Daniel M Hafez; Kavelin Rumalla; Laurie Bailey; Sabrina Shandley; Ashton Roach; Erin Alexander; Wendy Jenkins; Deki Tsering; George Price; Antonio Meola; Wendi Evanoff; Eric M Thompson; Nicholas Brandmeir Journal: J Neurosurg Pediatr Date: 2020-03-27 Impact factor: 2.375